Tags

Type your tag names separated by a space and hit enter

Baricitinib: From Rheumatoid Arthritis to COVID-19.
J Clin Pharmacol. 2021 10; 61(10):1274-1285.JC

Abstract

Baricitinib is a JAK1/2 inhibitor that was first approved for treating moderate to severe rheumatoid arthritis (RA) but that later showed considerable efficacy in the control of exaggerated inflammatory responses that occur in a wide range of diseases. There is a growing body of evidence, obtained from clinical trials and case reports, demonstrating clinical and paraclinical improvement in patients following administration of baricitinib including RA, systemic lupus erythematosus, psoriasis, atopic dermatitis, alopecia areata, interferon-mediated autoinflammatory diseases, graft-versus-host disease, diabetic kidney disease, and, recently, coronavirus disease-19. However, despite overall encouraging results, many adverse effects have been observed in baricitinib-treated patients, ranging from simple infections to increased risk of malignancies, particularly in long-term use. The significant efficacy of baricitinib, versus the probable adverse effects, urge further investigation before establishing it as a part of standard therapeutic protocols. Here, we have provided a review of the studies that have used baricitinib for treating various inflammatory disorders and summarized the advantages and disadvantages of its administration.

Authors+Show Affiliations

Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran.Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.Department of Chemical Engineering-Pharmaceutical Engineering, University of Tehran, Tehran, Iran.Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran.Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33870531

Citation

Assadiasl, Sara, et al. "Baricitinib: From Rheumatoid Arthritis to COVID-19." Journal of Clinical Pharmacology, vol. 61, no. 10, 2021, pp. 1274-1285.
Assadiasl S, Fatahi Y, Mosharmovahed B, et al. Baricitinib: From Rheumatoid Arthritis to COVID-19. J Clin Pharmacol. 2021;61(10):1274-1285.
Assadiasl, S., Fatahi, Y., Mosharmovahed, B., Mohebbi, B., & Nicknam, M. H. (2021). Baricitinib: From Rheumatoid Arthritis to COVID-19. Journal of Clinical Pharmacology, 61(10), 1274-1285. https://doi.org/10.1002/jcph.1874
Assadiasl S, et al. Baricitinib: From Rheumatoid Arthritis to COVID-19. J Clin Pharmacol. 2021;61(10):1274-1285. PubMed PMID: 33870531.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baricitinib: From Rheumatoid Arthritis to COVID-19. AU - Assadiasl,Sara, AU - Fatahi,Yousef, AU - Mosharmovahed,Banafsheh, AU - Mohebbi,Bahareh, AU - Nicknam,Mohammad Hossein, Y1 - 2021/06/12/ PY - 2021/01/02/received PY - 2021/04/11/accepted PY - 2021/4/20/pubmed PY - 2021/9/21/medline PY - 2021/4/19/entrez KW - COVID-19 KW - Janus kinase inhibitors KW - atopic dermatitis KW - baricitinib KW - psoriasis KW - rheumatoid arthritis SP - 1274 EP - 1285 JF - Journal of clinical pharmacology JO - J Clin Pharmacol VL - 61 IS - 10 N2 - Baricitinib is a JAK1/2 inhibitor that was first approved for treating moderate to severe rheumatoid arthritis (RA) but that later showed considerable efficacy in the control of exaggerated inflammatory responses that occur in a wide range of diseases. There is a growing body of evidence, obtained from clinical trials and case reports, demonstrating clinical and paraclinical improvement in patients following administration of baricitinib including RA, systemic lupus erythematosus, psoriasis, atopic dermatitis, alopecia areata, interferon-mediated autoinflammatory diseases, graft-versus-host disease, diabetic kidney disease, and, recently, coronavirus disease-19. However, despite overall encouraging results, many adverse effects have been observed in baricitinib-treated patients, ranging from simple infections to increased risk of malignancies, particularly in long-term use. The significant efficacy of baricitinib, versus the probable adverse effects, urge further investigation before establishing it as a part of standard therapeutic protocols. Here, we have provided a review of the studies that have used baricitinib for treating various inflammatory disorders and summarized the advantages and disadvantages of its administration. SN - 1552-4604 UR - https://www.unboundmedicine.com/medline/citation/33870531/Baricitinib:_From_Rheumatoid_Arthritis_to_COVID_19_ L2 - https://doi.org/10.1002/jcph.1874 DB - PRIME DP - Unbound Medicine ER -